Line S Tarpgaard
Overview
Explore the profile of Line S Tarpgaard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
243
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Detlefsen S, Burton M, Ainsworth A, Fristrup C, Graversen M, Pfeiffer P, et al.
Pleura Peritoneum
. 2024 Jul;
9(2):79-91.
PMID: 38948326
Objectives: Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) is an experimental treatment option in peritoneal metastasis from pancreatic cancer (PM-PC). Aims were to examine mRNA profile of fibrosis due to response after...
2.
Kryh-Jensen C, Fristrup C, Ainsworth A, Detlefsen S, Mortensen M, Pfeiffer P, et al.
Pleura Peritoneum
. 2023 Dec;
8(4):147-155.
PMID: 38144215
Objectives: A definition of long-term survival (LTS) in patients with peritoneal metastasis (PM) from gastric cancer (GC), pancreatic cancer (PC) or colorectal cancer (CRC) treated with systemic chemotherapy and pressurized...
3.
Fallah M, Detlefsen S, Ainsworth A, Fristrup C, Mortensen M, Pfeiffer P, et al.
Pleura Peritoneum
. 2022 Sep;
7(3):143-148.
PMID: 36159216
Objectives: The four-tiered peritoneal regression grading score (PRGS) is used for histological response evaluation in patients with peritoneal metastasis (PM) treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC). Four quadrant biopsies...
4.
Tarpgaard L, Qvortrup C, Nielsen S, Stenvang J, Detlefsen S, Brunner N, et al.
Acta Oncol
. 2021 Mar;
60(7):954-956.
PMID: 33783307
No abstract available.
5.
Jeppesen S, Bentsen K, Jorgensen T, Holm H, Holst-Christensen L, Tarpgaard L, et al.
Acta Oncol
. 2020 Oct;
60(1):4-12.
PMID: 33031010
Background: The COVID-19 pandemic is an international public health crisis. The risk of getting an infection with COVID-19 might impact the emotional well-being in patients with cancer. The aim of...
6.
Tarpgaard L, Orum-Madsen M, Christensen I, Nordgaard C, Noer J, Guren T, et al.
Oncotarget
. 2016 Aug;
7(37):59441-59457.
PMID: 27509063
It is now widely accepted that therapeutic antibodies targeting epidermal growth factor receptor (EGFR) can have efficacy in KRAS wild-type advanced colorectal cancer (CRC) patients. What remains to be ascertained...
7.
Tarpgaard L, Qvortrup C, Nygard S, Nielsen S, Andersen D, Jensen N, et al.
BMC Cancer
. 2016 Feb;
16:91.
PMID: 26867764
Unlabelled: The overall purpose of this study is to provide proof of concept for introducing the anthracycline epirubicin as an effective, biomarker-guided treatment for metastatic colorectal cancer (mCRC) patients who...
8.
Lin X, Stenvang J, Heilskov Rasmussen M, Zhu S, Jensen N, Tarpgaard L, et al.
BMC Genomics
. 2015 May;
16:404.
PMID: 25997618
Background: Irinotecan (SN38) and oxaliplatin are chemotherapeutic agents used in the treatment of colorectal cancer. However, the frequent development of resistance to these drugs represents a considerable challenge in the...
9.
Jensen N, Stenvang J, Beck M, Hanakova B, Belling K, Do K, et al.
Mol Oncol
. 2015 Mar;
9(6):1169-85.
PMID: 25759163
Current standard treatments for metastatic colorectal cancer (CRC) are based on combination regimens with one of the two chemotherapeutic drugs, irinotecan or oxaliplatin. However, drug resistance frequently limits the clinical...
10.
Tarpgaard L, Christensen I, Hoyer-Hansen G, Lund I, Guren T, Glimelius B, et al.
Int J Cancer
. 2015 Feb;
137(10):2470-7.
PMID: 25664394
Circulating forms of the urokinase plasminogen activator receptor (uPAR) are associated with prognosis in patients with colorectal cancer. Preclinical studies have shown that uPAR can influence the state of phosphorylation...